Sacituzumab Govitecan in Recurrent Glioblastoma
Sacituzumab Govitecan in Recurrent Glioblastoma
Recruiting · NCT04559230 · Registry updated 2026-03-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Sacituzumab Govitecan in Recurrent Glioblastoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2026-03-30 | NCT04559230 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| The University of Texas Health Science Center at San Antonio | 127 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cleveland Clinic Taussig Cancer Center | Cleveland | United States | 2 |
| Texas Oncology Austin | Austin | United States | 1 |
| University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center | San Antonio | United States | 2 |